Herein, we identified IGF2BP2 as a regulator of the m6A modification of CSF2, which in turn mediated the transformation of carcinoma-associated MSCs, which provides novel insights into the biological roles of m6A modification in MSC reprogramming in cancer. Here, IGF2BP2 is linked to carcinoma.